Find the right fit for you - faster
Get tailored insights about working at EiRx Therapeutics in one quick step.
EiRx Therapeutics Snapshot
EiRx Therapeutics wants to find out why a cell decides to live or die in order to develop the best drug therapies for colorectal and breast cancer. The biotechnology company has conducted research on apoptosis (programmed cell death) and biological drug resistance in tumors. It has put new drug candidates into early stage clinical trials and then licensed them to pharmaceutical companies for upfront fees and success-based royalties. Pharmaceutical companies that have licensed from EiRx include Merck & Co., OSI Pharmaceuticals, and ReGen Therapeutics Plc. The company is experiencing financial difficulties and has placed its development subsidiary, EiRx Therapeutics Limited, into liquidation.
